Enanta Pharmaceuticals Inc. Common Stock (ENTA)

FairStock Score: 47/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Enanta through the Graham lens first: is there a durable business with earnings and assets behind the price? The company is a 120-employee biotechnology firm trying to develop small-molecule drugs for virology and immunology. It has no Lynch category because it has lost money in each of the last four years, and the FairStock figures show why: trailing free cash flow is -$36.9M and the FCF yield is -11.0%. In fiscal Q3 2026, the quarter ended 2026-06-30, revenue was $14.4M and net income was -$19.5M, or -$0.67 per diluted share. Fiscal Q3 2025 had revenue of $18.3M and net income of -$18.3M. For FY2025, revenue was $65.3M and net income was -$81.9M; FY2024 revenue was $67.6M with a -$116.0M loss. Losses narrowed, but revenue shrank, and trailing metrics remain ugly. At the 2026-10-13 close of $11.52, the FairStock P/B is 3.32, ROE is -70.12%, ROCE is -12.28%, and debt-to-equity is 1.80. The Piotroski score is 1/9 and Altman Z-score is -0.63 - both signal financial fragility. The 52-week range is $10.20 to $17.15, so the shares are near the low end, but cheapness alone is not value when losses persist. FairStock gives it a 47/100 score. The pipeline may hold option value, but I see no moat in the filed numbers, no profits, and no margin of safety in the stated numbers. This is a speculative drug-development story, not a Graham bargain.

In plain English: Enanta is a small biotech company that tries to discover and develop drugs for viral infections. It has been losing money for years, revenue has been falling, and it burns cash, so the business looks weak. At the recent price, the stock looks speculative rather than cheap based on the company's own numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-06-30) · fiscal Q2 2026 10-Q (period ended 2026-03-31) · fiscal Q1 2026 10-Q (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-09-30) · FY2024 10-K (period ended 2024-09-30) · FY2023 10-K (period ended 2023-09-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer